The Saudade Pharma team has been involved in the development of several different medicinal products in different indications, a selection of which is shown below.
Cristal Therapeutics has developed a pioneering approach to transform drugs into tailor-made nanoparticles via its proprietary polymeric technology, registered as CriPec®. Recently, a phase II clinical trial in ovarian cancer was initiated with frontrunner CriPec® docetaxel. Saudade Pharma has been extensively involved in the development, scale-up and cGMP production of this novel nanomedicine.
The lead compound of Convert Pharmaceuticals is a hypoxia-activated prodrug (HAP). Hypoxia constitutes an important therapeutic obstacle as it promotes the development of resistance to conventional anti-cancer treatments. Saudade Pharma is supporting Convert with CMC related activities required for bringing the lead compound to the clinic in 2019.
Matisse Pharmaceuticals is a biotechnology company dedicated to the development of pharmaceutical therapies for disorders associated with fulminant inflammation such as sepsis. The most advanced product in development is the heparin fraction M6229 to treat severe sepsis and septic shock.
In the search of a better treatment for cardiovascular diseases, Mirabilis Therapeutics is using antisense oligonucleotides to downregulate the expression of specific microRNAs that are responsible for the pathological myocardial changes leading to heart failure. Saudade Pharma is supporting Mirabilis with the CMC activities required to compile an IMPD to support the phase I clinical submission.